Compare SST & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SST | MNOV |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.7M | 72.7M |
| IPO Year | N/A | 2005 |
| Metric | SST | MNOV |
|---|---|---|
| Price | $4.16 | $1.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $10.00 | $7.00 |
| AVG Volume (30 Days) | 30.6K | ★ 89.6K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,784,000.00 | $257,917.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.90 | $1.13 |
| 52 Week High | $15.00 | $2.24 |
| Indicator | SST | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 46.75 | 51.73 |
| Support Level | $4.07 | $1.47 |
| Resistance Level | $5.00 | $1.55 |
| Average True Range (ATR) | 0.43 | 0.05 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 37.12 | 42.11 |
System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.